These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 28034989)

  • 1. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.
    Ghermezi M; Li M; Vardanyan S; Harutyunyan NM; Gottlieb J; Berenson A; Spektor TM; Andreu-Vieyra C; Petraki S; Sanchez E; Udd K; Wang CS; Swift RA; Chen H; Berenson JR
    Haematologica; 2017 Apr; 102(4):785-795. PubMed ID: 28034989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
    Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR
    Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma.
    Guo P; Wang Y; He H; Chen D; Liu J; Qiang W; Lu J; Liang Y; Du J
    Clin Exp Immunol; 2024 Aug; 217(3):221-232. PubMed ID: 38743453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy.
    Bujarski S; Udd K; Soof C; Chen H; Spektor TM; Safaie T; Li M; Stern J; Wang C; Xu N; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Regidor B; Sutanto C; Berenson JR
    Target Oncol; 2021 Jul; 16(4):503-515. PubMed ID: 34097243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment.
    Jew S; Chang T; Bujarski S; Soof C; Chen H; Safaie T; Li M; Sanchez E; Wang C; Spektor TM; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Berenson JR
    Br J Haematol; 2021 Jan; 192(2):272-280. PubMed ID: 32441777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of cystatin C in multiple myeloma.
    Zhang J; Jiang Y; Guo D; Liu HY; Hong L; Qi J; Huang H
    Int J Lab Hematol; 2022 Feb; 44(1):135-141. PubMed ID: 34549533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.
    Sanchez E; Li M; Kitto A; Li J; Wang CS; Kirk DT; Yellin O; Nichols CM; Dreyer MP; Ahles CP; Robinson A; Madden E; Waterman GN; Swift RA; Bonavida B; Boccia R; Vescio RA; Crowley J; Chen H; Berenson JR
    Br J Haematol; 2012 Sep; 158(6):727-38. PubMed ID: 22804669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating a normal reference range for serum B-cell maturation antigen levels for multiple myeloma patients.
    Jew S; Bujarski S; Soof C; Chen H; Safaie T; Li M; Sanchez E; Wang C; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Spektor TM; Berenson JR
    Br J Haematol; 2021 Mar; 192(6):1064-1067. PubMed ID: 32321191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Suppressed Levels of Uninvolved Immunoglobulins on the Prognosis of Symptomatic Multiple Myeloma.
    Sarı M; Sarı S; Nalçacı M
    Turk J Haematol; 2017 Jun; 34(2):131-136. PubMed ID: 27795224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
    Lee L; Bounds D; Paterson J; Herledan G; Sully K; Seestaller-Wehr LM; Fieles WE; Tunstead J; McCahon L; Germaschewski FM; Mayes PA; Craigen JL; Rodriguez-Justo M; Yong KL
    Br J Haematol; 2016 Sep; 174(6):911-22. PubMed ID: 27313079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma.
    Ma T; Shi J; Xiao Y; Bian T; Wang J; Hui L; Wang M; Liu H
    Front Immunol; 2021; 12():724411. PubMed ID: 34867949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
    Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
    Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of bone marrow histology in multiple myeloma.
    Subramanian R; Basu D; Dutta TK
    Indian J Cancer; 2009; 46(1):40-5. PubMed ID: 19282565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
    Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
    Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy.
    Bernabei L; Tian L; Garfall AL; Melenhorst JJ; Lacey SF; Stadtmauer EA; Vogl DT; Gonzalez VE; Plesa G; Young RM; Waxman A; Levine BL; June CH; Milone MC; Cohen AD
    Br J Haematol; 2021 May; 193(4):851-855. PubMed ID: 33713436
    [No Abstract]   [Full Text] [Related]  

  • 17. Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma.
    Wiedemann Á; Szita VR; Horváth R; Szederjesi A; Sebő A; Tóth AD; Masszi T; Varga G
    Pathol Oncol Res; 2023; 29():1611171. PubMed ID: 37188125
    [No Abstract]   [Full Text] [Related]  

  • 18. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
    Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
    Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
    Ali SA; Shi V; Maric I; Wang M; Stroncek DF; Rose JJ; Brudno JN; Stetler-Stevenson M; Feldman SA; Hansen BG; Fellowes VS; Hakim FT; Gress RE; Kochenderfer JN
    Blood; 2016 Sep; 128(13):1688-700. PubMed ID: 27412889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of soluble B cell maturation antigen as a biomarker in multiple myeloma.
    Alomari M; Kunacheewa C; Manasanch EE
    Leuk Lymphoma; 2023 Feb; 64(2):261-272. PubMed ID: 36282671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.